TP53 and cancer: TP53 p.R337H is hypomorphic (i.e., a low-penetrance variant in more than 50% of our large cohort) [2,5,14] in contrast to the lifetime cancer risk of germline TP53 gene variants in classic LFS carriers, affecting over 70% of males and nearly 100% of females [20].